- Home
- ANEB vs FGEN Comparison
ANEB vs FGEN Comparison
Compare ANEB & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- FGEN
- Stock Information
- Founded
- ANEB 2020
- FGEN 1993
- Country
- ANEB United States
- FGEN United States
- Employees
- ANEB N/A
- FGEN N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- FGEN Health Care
- Exchange
- ANEB Nasdaq
- FGEN Nasdaq
- Market Cap
- ANEB 36.7M
- FGEN 33.5M
- IPO Year
- ANEB 2021
- FGEN 2014
- Fundamental
- Price
- ANEB $0.98
- FGEN $0.30
- Analyst Decision
- ANEB Buy
- FGEN Strong Buy
- Analyst Count
- ANEB 1
- FGEN 1
- Target Price
- ANEB $8.00
- FGEN $10.00
- AVG Volume (30 Days)
- ANEB 37.4K
- FGEN 1.4M
- Earning Date
- ANEB 05-14-2025
- FGEN 05-05-2025
- Dividend Yield
- ANEB N/A
- FGEN N/A
- EPS Growth
- ANEB N/A
- FGEN N/A
- EPS
- ANEB N/A
- FGEN N/A
- Revenue
- ANEB N/A
- FGEN $29,621,000.00
- Revenue This Year
- ANEB N/A
- FGEN $544.98
- Revenue Next Year
- ANEB N/A
- FGEN $9.45
- P/E Ratio
- ANEB N/A
- FGEN N/A
- Revenue Growth
- ANEB N/A
- FGEN N/A
- 52 Week Low
- ANEB $0.80
- FGEN $0.18
- 52 Week High
- ANEB $3.30
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- ANEB 35.89
- FGEN 43.82
- Support Level
- ANEB $0.94
- FGEN $0.23
- Resistance Level
- ANEB $1.12
- FGEN $0.29
- Average True Range (ATR)
- ANEB 0.14
- FGEN 0.03
- MACD
- ANEB -0.03
- FGEN 0.01
- Stochastic Oscillator
- ANEB 11.17
- FGEN 62.26
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.